- People
- Offices
- Capabilities
back- Capabilities
- Corporate, Finance and Investments
- back
- Corporate, Finance and Investments
- Overview
- Activist Defense
- Banking and Institutional Finance
- Capital Markets
- Construction and Procurement
- Corporate Governance
- Emerging Companies and Venture Capital
- Employee Benefits and Executive Compensation
- Energy and Infrastructure Projects
- Financial Restructuring
- Global Human Capital and Compliance
- Investment Funds and Asset Management
- Mergers and Acquisitions (M&A)
- Middle East and Islamic Finance and Investment
- Private Credit & Special Situations
- Private Equity
- Public Companies
- Real Estate
- Structured Finance and Securitization
- Tax
- Technology Transactions
- Government Matters
- back
- Government Matters
- Overview
- Antitrust
- Data, Privacy and Security
- Environmental, Health and Safety
- FDA and Life Sciences
- Government Advocacy and Public Policy
- Government Contracts
- Healthcare
- International Trade
- National Security and Corporate Espionage
- Securities Enforcement and Regulation
- Special Matters and Government Investigations
- Trial and Global Disputes
- back
- Trial and Global Disputes
- Overview
- Antitrust
- Appellate, Constitutional and Administrative Law
- Bankruptcy and Insolvency Litigation
- Class Action Defense
- Commercial Litigation
- Construction and Engineering Disputes
- Corporate and Securities Litigation
- E-Discovery
- Intellectual Property
- International Arbitration and Litigation
- Labor and Employment
- Product Liability
- Professional Liability
- Toxic & Environmental Torts
- Industries / Issues
- back
- Industries / Issues
- Automotive, Transportation and Mobility
- Energy
- Financial Services
- Food and Beverage
- Higher Education
- Life Sciences and Healthcare
- Technology
- #MeToo
- Buy American
- COVID-19 Vaccine Rollout
- Crisis Management
- Environmental Agenda
- Environmental, Social and Governance (ESG)
- Focus on Women's Health
- Russia/Ukraine
- Special Purpose Acquisition Companies (SPACs)
- Careers
- News & Insights
- About
- Languages
Jeffrey S. Bucholtz
Insights 27 results
Article · Source: U.S. Chamber of Commerce Litigation Center Blog
October 13, 2022
Top False Claims Act Developments
Article · Source: Chamber Litigation Blog
May 25, 2021
Stats Without Facts: Another Court Rejects Data Mining Qui Tam Strategy
Client Alert
July 30, 2020
Trump Administration Continues to Promote Drug Importation as a Way to Lower the Cost of Prescription Drugs
Article · Source: Chamber Litigation Blog
June 10, 2020
The Nuisance of Nuisance Litigation
Client Alert
April 28, 2020
Constitutional Limitations On Emergency Authority
Client Alert
April 9, 2020
False Claims Act Considerations Related to the CARES Act's Small Business Administration Loan Program
Client Alert
September 24, 2018
Echoes of the Brand Memo
Client Alert
January 31, 2018
The Brand Memorandum: DOJ Restricts Reliance on Agency Guidance in Civil Enforcement Actions
Client Alert
January 26, 2017
FDA Defends Its First Amendment Position in “Memorandum”
Client Alert
January 19, 2017
FDA Takes Action in the Last Days of the Obama Administration to Clarify Some of Its Views on Off-Label Communications
Client Alert
November 1, 2016
FDA Launches Form for Reporting Allegations of Misconduct by Device Manufacturers
Client Alert
June 20, 2016
Universal Health Services v. Escobar